Drug intelligence / Profile preview

MGY2333-CAR

Development stage: Preclinical
Lead developer: IMMUNISBIO
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

MGY2333-CAR is a preclinical-stage chimeric antigen receptor natural killer (CAR-NK) cell therapy being developed by Immunisbio. The program is specifically targeted toward the treatment of head and neck cancer. As a CAR-NK therapy, it involves the genetic modification of natural killer cells to express a chimeric antigen receptor, enhancing their ability to recognize and eliminate malignant cells. Immunisbio utilizes its proprietary NK cell activation and expansion technology as the foundation for this CAR-NK candidate.

Other names: MGY2333MGY-2333MGY 2333

Beyond the preview

Go deeper on MGY2333-CAR.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MGY2333-CAR.

Explore the full profile